New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 12, 2013
07:11 EDTBSXOrbusNeich announces favorable ruling from European Patent Office
OrbusNeich Medical announced that it received a favorable ruling from the European Patent Office yesterday in connection with its European Patent EP1 341 482. The '482 patent covers certain novel stents with helical structures. It was issued by the EPO to OrbusNeich in October 2010 and does not expire until December 2021. In July 2011, Boston Scientific Corporation and Terumo Kabushiki Kaisha filed oppositions asking the EPO to revoke the '482 patent, asserting that the patent was invalid.
News For BSX From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
November 20, 2014
07:31 EDTBSXBoston Scientific should be bought on weakness, says RBC Capital
Subscribe for More Information
November 19, 2014
12:11 EDTBSXBoston Scientific says Synergy stent met primary endpoint in trial
In the first successful U.S. pivotal trial of a bioabsorbable polymer stent, the Boston Scientific SYNERGY Everolimus-Eluting Bioabsorbable Polymer Platinum Chromium Coronary Stent System met its primary endpoint in this non-inferiority study, which evaluated the one-year rate of target lesion failure. Additionally, favorable rates for key secondary endpoints were observed with the SYNERGY Stent. Dean Kereiakes, M.D., F.A.C.C., F.S.C.A.I., the principal investigator for the EVOLVE II Trial, presented the study results today in a Late Breaking Clinical Trial session at the American Heart Association Scientific Session 2014 in Chicago. Key findings for the SYNERGY Stent from the EVOLVE II Trial include the following: At 12 months, the TLF rate was 6.4% per protocol and 6.7% for intent-to-treat. Stent Thrombosis was rare, with Definite or Probable ST occurring in only 0.4% of patients through one year. No Definite ST occurred after 24 hours.
06:30 EDTBSXJohnson & Johnson, Boston Scientific trial set to start tomorrow, Reuters says
Subscribe for More Information
November 18, 2014
11:35 EDTBSXBoston Scientific November volatility elevated into investor day
Subscribe for More Information
07:37 EDTBSXStifel to hold a conference
Subscribe for More Information
06:08 EDTBSXBoston Scientific to host investor meeting
Investor meeting to be held on November 19 at 2 pm. Webcast Link
November 17, 2014
09:08 EDTBSXBoston Scientific announces first U.S. procedures with Symphion completed
Subscribe for More Information
November 14, 2014
12:53 EDTBSXOmega Advisors gives quarterly update on stakes
NEW STAKES: AerCap Holdings (AER), Nordic American Offshore (NAO), Melco Crown Entertainment (MPEL), Groupon (GRPN), and Ashland (ASH). INCREASED STAKES: QEP Resources (QEP), United Continental (UAL), Cabot Oil & Gas (COG), Actavis (ACT), and KAR Auction Services (KAR). DECREASED STAKES: Sprint (S), SandRidge Energy (SD), Sirius XM Holdings (SIRI), Kinder Morgan (KMI), and Transocean (RIG). LIQUIDATED STAKES: QUALCOMM (QCOM), Ocwen Financial (OCN), Freeport-McMoRan (FCX), Boston Scientific (BSX), and Capital One (COF).

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use